Molecular determinants of myeloma bone disease and uses thereof

Details Molecular determinants of myeloma bone disease and uses thereof Molecular determinants of myeloma bone disease and uses thereof

2003-12-04

2008-12-02

Fetterolf, Brandon J (Department: 1642)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C435S007100, C435S007230

Reexamination Certificate

active

07459437

ABSTRACT:
To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3/FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P<0.05). DKK1 and FRZB were not expressed in plasma cells from 45 normal bone marrow donors or 10 Waldenstrom's macroglobulinemia, a related plasma cells malignancy that lacks bone disease. These data indicate that these factors are important mediators of multiple myeloma bone disease, and inhibitors of these proteins may be used to block bone disease.

REFERENCES:
patent: 20040038860 (2004-02-01), None
patent: WO 0052047 (2000-09-01), None
patent: WO 0052047 (2000-09-01), None
Chappuis et al. (Cancer Treat Res. 2002; 107: 29-59).
McLaughlin et al. (Tannock, I.F. and Hill, R.P., The Basic Science of Oncology, Chapter 2, (3rd Ed., 1998)).
Stevenson et al. (BMJ 1989; 298: 924-928).
Soroko et al. (J. Bone Miner. Res. 1994; 9: 761-769).
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Slamon et al. (Science vol. 235, Jan. 1987, pp. 177-182).
Verma et al. (1997) Nature vol. 389, pp. 239-242.
Marshall (1995) Science, vol. 269, Issue 5227, pp. 1050-1055.
Eck et al. (Goodman & Gilman's The Pharmacological Basis of Therapeutics (1996), 9th Edition, Chapter 5, McGraw-Hill, NY).
Juengst (British Medical Journal (2003) vol. 326, pp. 1410-1411).
Rubanyi (Mol. Aspects Med. (2001) 22:113-142).
Zhang, Y. et al. The LRP5 High-Bone-Mass G171 Mutation Disrupts LRP5 Interaction with Mesd:Molecular and Cellular Biology, Jun. 2004, vol. 24, No. 11, pp. 4677-4684.
Boyden, L. M. et al. High Bone Density Due to a Mutation in LDL-Receptor-Related Protein 5:N Engl J Med, May 16, 2002, vol. 346, No. 20, pp. 1513-1521.
Little, R.D. et al.; A Mutation in the LDL Receptor-Related Protein 5 Gene Results in the Autosomal Dominant High-Bone-Mass Trait:Am. J. Hum. Genet., 2002 vol. 70, pp. 11-19.

Affiliated with

Also associated with

Rating

Molecular determinants of myeloma bone disease and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Molecular determinants of myeloma bone disease and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Molecular determinants of myeloma bone disease and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4044004